Flovent
Product Images NDC 50090-0916

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Flovent (NDC 50090-0916). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Propionate Chemical Structure (Floventhfa Spl Graphic 01)

Chemical structure diagram depicting the molecular structure of the active ingredient in FLOVENT HFA. The diagram shows carbon rings with attached functional groups including hydroxyl, fluorine, and ester groups, illustrating the specific arrangement of atoms and bonds in the compound.*

FDA Label Image

Figure 1. A 12-week Clinical Trial In Subjects Aged 12 Years And Older Inadequately Controlled On Bronchodilators Alone: Mean Percent Change From Baseline In Fev1 Prior To Am Dose (trial 1) (Floventhfa Spl Graphic 02)

Line graph showing the percentage change from baseline in FEV1 (Forced Expiratory Volume in 1 second) over 12 weeks, comparing Placebo and FLOVENT HFA 88 mcg twice daily. The x-axis represents weeks, and the y-axis represents percent change from baseline. FLOVENT HFA shows a greater increase over time compared to Placebo.*

FDA Label Image

Figure 2. A 12-week Clinical Trial In Subjects Aged 12 Years And Older Already Receiving Daily Inhaled Corticosteroids: Mean Percent Change From Baseline In Fev1 Prior To Am Dose (trial 2) (Floventhfa Spl Graphic 03)

A line graph showing the percent change from baseline in FEV1 over a 12-week period and at the endpoint. It compares placebo and three different doses of FLOVENT HFA inhaler: 88 mcg, 220 mcg, and 440 mcg taken twice daily. The y-axis represents percentage change from baseline in FEV1, and the x-axis represents weeks of treatment and endpoint.*

FDA Label Image

Figure 3. A 16-week Clinical Trial In Subjects Aged 12 Years And Older Requiring Chronic Oral Prednisone Therapy: Change In Maintenance Prednisone Dose (Floventhfa Spl Graphic 04)

A bar chart comparing the percentage of subjects experiencing a 100% reduction in dose or an increase in dose across three groups: Placebo, FLOVENT HFA 440 mcg twice daily, and FLOVENT HFA 880 mcg twice daily. The chart uses solid black for Placebo, white for FLOVENT HFA 440 mcg twice daily, and diagonal stripes for FLOVENT HFA 880 mcg twice daily.*

FDA Label Image

Figure A (Floventhfa Spl Graphic 05)

An illustration diagram of a FLOVENT HFA inhaler showing its labeled parts: a metal canister, dark orange plastic actuator, dark orange mouthpiece with a counter displaying 124 doses, and a separate peach-colored cap designed to cover the mouthpiece.*

FDA Label Image

Figure B (Floventhfa Spl Graphic 06)

Instructional diagram showing a person holding a FLOVENT HFA inhaler in one hand and removing or inspecting the mouthpiece cover with the other hand, indicated by an arrow pointing from the cover to the inhaler.*

FDA Label Image

Fgure C (Floventhfa Spl Graphic 07)

Illustration showing a person using an inhaler labeled with the dosage '125'. The image demonstrates holding the inhaler upright and pressing down on the top to release a spray, with a cap removed and placed on the surface below.*

FDA Label Image

Figure D (Floventhfa Spl Graphic 08)

Illustration showing a hand holding a FLOVENT HFA inhaler with a dose counter displaying the number 120. The image demonstrates how to hold the inhaler properly for use.*

FDA Label Image

Figure E (Floventhfa Spl Graphic 09)

An illustration diagram showing the proper mouthpiece-down position for using the Flovent HFA inhaler. The image highlights a dark orange mouthpiece on the inhaler and a separate peach-colored cap.*

FDA Label Image

Figure F (Floventhfa Spl Graphic 10)

An instructional illustration showing a person exhaling, accompanied by the text 'Breathe out as much air as you can.' An arrow illustrates the direction of the exhaled air from the mouth. The image instructs on proper breathing technique, likely related to inhaler use.*

FDA Label Image

Figure G (Floventhfa Spl Graphic 11)

Instructional illustration showing a person using an inhaler. The image depicts the inhaler being held close to the mouth with an arrow indicating to push down and breathe in, emphasizing correct inhaler use.*

FDA Label Image

Figure H (Floventhfa Spl Graphic 12)

An instructional illustration showing a person rinsing their mouth by spitting water into a sink with a glass of water positioned on the sink's edge. This image is likely related to post-inhaler use mouth rinsing instructions.*

FDA Label Image

Figure I (Floventhfa Spl Graphic 13)

An instructional diagram showing correct inhaler use. The top image labeled 'Not blocked' depicts the inhaler spray releasing properly. The bottom image labeled 'Blocked' shows the spray being obstructed, illustrating the effect on medication delivery.*

FDA Label Image

Floventhfa Spl Graphic 14

An instructional illustration showing a hand holding a swab or cotton applicator cleaning the mouthpiece of an inhaler by rotating the swab inside the mouthpiece area. The drawing focuses on proper maintenance of the inhaler's mouthpiece.*

FDA Label Image

Label Image (Lbl500900916)

FLOVENT HFA (Fluticasone Propionate Inhalation Aerosol) 44 mcg label from A-S Medication Solutions. The label includes dosage instructions, product number 5671-0, net weight 10.6 g, and 120 metered actuations. It also features the Product NDC 50090-0916-0 with distribution information indicating Libertyville, Illinois.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.